RxDoctor Payments Data

Yamen Korab, MD

Family Medicine · Crowley, LANPI 1073712022

Payments from drug & device makers

$1,143in general payments, 2019–2025

Across 61 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$151
  • Supernus Pharmaceuticals, Inc.$126
  • AbbVie$120
  • Pfizer$110
  • Teladoc Health, Inc.$100
  • GSK$91
  • plus $444 from 16 others

What the payments were for

  • Speaking & faculty fees$1009%
  • Food & beverage$1,01389%
  • Education$303%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,143 in reported general payments places this provider in the 55th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$11,961
Medicare patients
50
Services billed
148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide54$42,543
MounjaroTirzepatide16$20,811
OzempicSemaglutide17$17,872
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$9,363
Lantus SolostarInsulin Glargine,hum.Rec.Anlog61$7,733
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,636
Gabapentin94$1,933
Albuterol Sulfate HfaAlbuterol Sulfate31$1,401
Quetiapine Fumarate40$1,269
Omeprazole71$1,255
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine24$965
Atorvastatin Calcium96$933
Metoprolol Succinate59$779
Rosuvastatin Calcium30$631
Metformin Hcl84$626

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$120$42,54354 claims
Lilly USA, LLCMounjaro$19$20,81116 claims
GSKTrelegy Ellipta$91$6,63611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Crowley

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →